438 related articles for article (PubMed ID: 31364476)
21. A Novel Double
Mathew A; Latteyer S; Frank-Raue K; Moeller LC; Zwanziger D; Mengel M; Führer D; Tiedje V
Thyroid; 2021 Feb; 31(2):327-329. PubMed ID: 32546069
[No Abstract] [Full Text] [Related]
22. A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung's disease.
Dvoráková S; Dvoráková K; Malíková M; Skába R; Vlcek P; Bendlová B
J Pediatr Surg; 2005 Jun; 40(6):e1-6. PubMed ID: 15991157
[TBL] [Abstract][Full Text] [Related]
23. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
24. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
[TBL] [Abstract][Full Text] [Related]
25. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form.
Figlioli G; Landi S; Romei C; Elisei R; Gemignani F
Mutat Res; 2013; 752(1):36-44. PubMed ID: 23059849
[TBL] [Abstract][Full Text] [Related]
26. Variability in Medullary Thyroid Carcinoma in
Mathiesen JS; Nielsen SG; Rasmussen ÅK; Kiss K; Wadt K; Hermann AP; Nielsen MF; Larsen SR; Brusgaard K; Frederiksen AL; Godballe C; Rossing M
Front Endocrinol (Lausanne); 2020; 11():251. PubMed ID: 32411094
[No Abstract] [Full Text] [Related]
27. Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA; Hatakana R; Lourenço DM; Lindsey SC; Camacho CP; Almeida M; Lima JV; Sekiya T; Garralda E; Naslavsky MS; Yamamoto GL; Lazar M; Meirelles O; Sobreira TJ; Lebrao ML; Duarte YA; Blangero J; Zatz M; Cerutti JM; Maciel RM; Toledo SP
Endocr Relat Cancer; 2015 Feb; 22(1):65-76. PubMed ID: 25425582
[TBL] [Abstract][Full Text] [Related]
28. RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.
Qi XP; Zhao JQ; Chen ZG; Cao JL; Du J; Liu NF; Li F; Sheng M; Fu E; Guo J; Jia H; Zhang YM; Ma JM
Oncotarget; 2015 Oct; 6(32):33993-4003. PubMed ID: 26356818
[TBL] [Abstract][Full Text] [Related]
29. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
[TBL] [Abstract][Full Text] [Related]
30. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
31. Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
Mathiesen JS; Habra MA; Bassett JHD; Choudhury SM; Balasubramanian SP; Howlett TA; Robinson BG; Gimenez-Roqueplo AP; Castinetti F; Vestergaard P; Frank-Raue K
J Clin Endocrinol Metab; 2017 Jun; 102(6):2069-2074. PubMed ID: 28323957
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.
Silva AL; Carmo F; Moura MM; Domingues R; Espadinha C; Leite V; Cavaco B; Bugalho MJ
Endocrine; 2015 Jun; 49(2):366-72. PubMed ID: 25725622
[TBL] [Abstract][Full Text] [Related]
33. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
34. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.
Frank-Raue K; Rybicki LA; Erlic Z; Schweizer H; Winter A; Milos I; Toledo SP; Toledo RA; Tavares MR; Alevizaki M; Mian C; Siggelkow H; Hüfner M; Wohllk N; Opocher G; Dvořáková S; Bendlova B; Czetwertynska M; Skasko E; Barontini M; Sanso G; Vorländer C; Maia AL; Patocs A; Links TP; de Groot JW; Kerstens MN; Valk GD; Miehle K; Musholt TJ; Biarnes J; Damjanovic S; Muresan M; Wüster C; Fassnacht M; Peczkowska M; Fauth C; Golcher H; Walter MA; Pichl J; Raue F; Eng C; Neumann HP;
Hum Mutat; 2011 Jan; 32(1):51-8. PubMed ID: 20979234
[TBL] [Abstract][Full Text] [Related]
35. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
36. Rare RET Variant p.D707E in a Chinese Pedigree with Hereditary Medullary Thyroid Carcinoma.
Zhang L; Li X; Li Q; Ge S; Chen M; Huang S; Chen B; Li P; Teng B; Xu J; Zhao S; Qi F; Zhang Y
Pathobiology; 2017; 84(3):152-160. PubMed ID: 27798940
[TBL] [Abstract][Full Text] [Related]
37. Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma.
Qi XP; Ying RB; Ma JM; Liu WT; Du ZF; Fei J; Yang CP; Song QZ; Jin HY; Chen ZG; Han JS; Wang JQ; Chen XL; Zhao Y; Lu JJ; Zhang XN
Fam Cancer; 2012 Mar; 11(1):131-6. PubMed ID: 22068382
[TBL] [Abstract][Full Text] [Related]
38. Elevated basal serum levels of calcitonin and simultaneous surgery of MEN2A-specific tumors.
Tang HX; Yang H; Li F; Cao ZL; Huang YT; Qi XP
Neoplasma; 2021 Sep; 68(5):1098-1106. PubMed ID: 34156257
[TBL] [Abstract][Full Text] [Related]
39. A Novel Germline Deletion of p.C630 in RET Causes MTC and Promotes Cell Proliferation and Sensitivity to Pralsetinib.
Ma X; Ma X; Chin L; Zhu Z; Han H
J Clin Endocrinol Metab; 2022 Aug; 107(9):2636-2643. PubMed ID: 35689816
[TBL] [Abstract][Full Text] [Related]
40. Surgical strategy in a kindred with a rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia.
Colombo-Benkmann M; Brämswig J; Höppner W; Gellner R; Hengst K; Böcker W; Senninger N
World J Surg; 2002 Oct; 26(10):1286-90. PubMed ID: 12205548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
